

# Marie-Camille Chaumais

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2978101/marie-camille-chaumais-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26

papers

889

citations

14

h-index

28

g-index

28

ext. papers

1,110

ext. citations

7.6

avg, IF

3.55

L-index

#	Paper	IF	Citations
26	Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. <i>Cardiovascular Research</i> , <b>2021</b> , 117, 1391-1401	9.9	5
25	Characteristics and Long-term Outcomes of Pulmonary Venocclusive Disease Induced by Mitomycin C. <i>Chest</i> , <b>2021</b> , 159, 1197-1207	5.3	5
24	Association between Leflunomide and Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , <b>2021</b> , 18, 1306-1315	4.7	0
23	Pulmonary hypertension associated with busulfan. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 20458940211030170	2.7	1
22	Evaluation of a program of pharmaceutical counseling for French patients on oral anticoagulant therapy. <i>International Journal of Clinical Pharmacy</i> , <b>2020</b> , 42, 685-694	2.3	2
21	Evaluation of a collaborative care program for pulmonary hypertension patients: a multicenter randomized trial. <i>International Journal of Clinical Pharmacy</i> , <b>2020</b> , 42, 1128-1138	2.3	0
20	Awareness campaigns of atrial fibrillation as an opportunity for early detection by pharmacists: an international cross-sectional study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 49, 606-617	5.1	12
19	Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. <i>European Respiratory Journal</i> , <b>2020</b> , 56,	13.6	57
18	Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	21
17	Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension. <i>International Journal of Clinical Pharmacy</i> , <b>2018</b> , 40, 790-794	2.3	3
16	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	62
15	Lung transplantation for mitomycin-induced pulmonary veno-occlusive disease. <i>Presse Medicale</i> , <b>2017</b> , 46, 1223-1225	2.2	4
14	Pulmonary arterial hypertension induced by tyrosine kinase inhibitors. <i>Current Opinion in Pulmonary Medicine</i> , <b>2017</b> , 23, 392-397	3	31
13	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 3207-18	15.9	144
12	Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. <i>European Respiratory Journal</i> , <b>2016</b> , 48, 1517-1519	13.6	36
11	Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models. <i>Circulation</i> , <b>2015</b> , 132, 834-47	16.7	80
10	Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. <i>Gastroenterology</i> , <b>2015</b> , 149, 1378-1380.e1	13.3	60

9	Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension. <i>American Journal of Cardiovascular Drugs</i> , <b>2015</b> , 15, 13-26	4	19
8	Pulmonary arterial hypertension in patients treated with interferon. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1851-3	13.6	9
7	Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1211-4	13.6	3
6	Chemotherapy-induced pulmonary hypertension: role of alkylating agents. <i>American Journal of Pathology</i> , <b>2015</b> , 185, 356-71	5.8	116
5	Pulmonary arterial hypertension in patients treated with interferon. <i>European Respiratory Journal</i> , <b>2014</b> , 44, 1627-34	13.6	66
4	Drugs induced pulmonary arterial hypertension. <i>Presse Medicale</i> , <b>2013</b> , 42, e303-10	2.2	22
3	Dispositif de formation d'une équipe pharmaceutique à la consultation d'accompagnement d'un patient sous traitement anticoagulant oral. <i>Pédagogie Médicale</i> , <b>2013</b> , 14, 269-283	0.2	1
2	Pulmonary hypertension associated with benfluorex exposure. <i>European Respiratory Journal</i> , <b>2012</b> , 40, 1164-72	13.6	60
1	A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 186, 666-76	10.2	68